Adobe stock slips premarket after Jefferies downgrade flags tougher AI fight

Adobe stock slips premarket after Jefferies downgrade flags tougher AI fight

NEW YORK, Jan 5, 2026, 06:11 ET — Premarket

  • Jefferies cut Adobe to Hold from Buy and lowered its price target to $400 from $500. MarketScreener
  • Adobe shares were down about 0.8% in premarket trading after ending the prior session at $333.30. Public

Shares of Adobe Inc (ADBE.O) fell about 0.8% to $330.6 in premarket trading on Monday after Jefferies downgraded the Photoshop maker to Hold from Buy and cut its price target to $400 from $500. The stock closed on Friday down 4.8%. StockAnalysis

The call lands as Wall Street starts the year reassessing software valuations, with investors pressing for proof that generative AI can lift paid subscriptions rather than widen the pool of free alternatives. Jefferies said 2026 is likely to bring only “gradual” AI monetization — turning AI features into paid revenue — and warned that “disintermediation” fears persist, meaning customers may bypass full software suites for standalone tools. TipRanks

Jefferies pointed to intensifying pressure in the lower end of Adobe’s market, where casual creators can choose from a growing menu of AI-enhanced options instead of subscribing to Creative Cloud. Analyst Brent Thill wrote that accelerating growth would be “more difficult without a step-function increase in creative AI mindshare” — shorthand for a sharp jump in user adoption and engagement with Adobe’s AI features. Investing

From a chart perspective, traders are watching the $330 area after Friday’s intraday low of $331.64, with overhead resistance near $350 after last week’s trading range topped out around $351. Adobe has traded in a 52-week range of $311.58 to $465.70, according to Investing.com. Investing

Beyond single-stock catalysts, markets face a heavy U.S. data calendar that can swing rate expectations and, by extension, valuation-sensitive tech stocks. The ISM manufacturing survey is due later Monday, the ISM services report follows on Wednesday, and the U.S. jobs report is scheduled for Friday; investors also have the Fed’s Jan. 27-28 policy meeting on the radar. Institute for Supply Management

Adobe last guided in December for fiscal 2026 revenue of $25.90 billion to $26.10 billion and adjusted earnings per share of $23.30 to $23.50, above analysts’ estimates compiled by LSEG. The company also said it would shift reporting to focus more on subscription revenue and year-ending annual recurring revenue. Reuters

Investors’ next company checkpoint is Adobe’s first-quarter fiscal 2026 earnings call on March 12, when they will look for traction in paid AI offerings and net new annual recurring revenue (ARR), a yardstick for subscription sales expected over a year. Adobe

Stock Market Today

  • Summit Therapeutics valuation under the microscope after share strength; P/B at 74.8x, DCF fair value $217.67
    January 7, 2026, 8:37 PM EST. Summit Therapeutics (SMMT) rose 1.9% on the day and 8.7% over the week, though longer-term returns remain uneven: 30 days up 2.07%, 90 days down 16.07%, and a three-year total shareholder return that highlights patient holders' gains despite near-term momentum cooling. On a P/B basis, the stock trades at 74.8x price against a US$19.01 share price, far above the industry average of 2.7x and a peer average of 11.2x, signaling the market expects a stronger future than the balance sheet implies. A DCF model puts fair value at US$217.67 versus last close of US$19.01, suggesting potential discount based on cash flow scenarios. The narrative flags OVERVALUED P/B and UNDERVALUED DCF; risk remains, including ongoing net losses of US$921.617 and potential ivonescimab trial failures.
ASML Holding stock pops on Bernstein upgrade as €1,300 target turns heads before Jan. 28 earnings
Previous Story

ASML Holding stock pops on Bernstein upgrade as €1,300 target turns heads before Jan. 28 earnings

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift
Next Story

Ironwood Pharmaceuticals stock rises premarket after Citizens upgrade, Wells Fargo target lift

Go toTop